Background: Ceramide is a core molecule of sphingolipid
metabolism that causes selective insulin resistance and dyslipidemia. Research
on its involvement in cardiovascular diseases has grown rapidly. Therefore, it
is necessary to unravel the role of ceramide in cardiovascular diseases.
Purpose: The focus of this review is to summarize the role of ceramide in
cardiovascular disease, and investigate the possible application of ceramide as
a new diagnostic biomarker and a therapeutic target for cardiovascular
disorders, and highlight the remaining problems.
Results: In resting cells, ceramide levels are extremely low, while they rapidly
accumulate upon encountering external stimuli. Increased ceramide levels are
strongly associated with adverse cardiovascular risks and events while
inhibiting the synthesis of ceramide or accelerating its degradation improves a
variety of cardiovascular diseases, including atherosclerosis, hypertension,
myocardial infarction, ischemia-reperfusion, and heart failure. Therefore,
ceramide is expected to be a core regulatory target which may have a broad
potential to combat CVDs.
Author(s) Details:
Hongyang Shu,
Division of Cardiology, Department of Internal Medicine, Tongji
Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430000, China and Hubei Key Laboratory of Genetics and
Molecular Mechanism of Cardiologic Disorders, Huazhong University of Science
and Technology, Wuhan 430000, China.
Yizhong
Peng,
Department
of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan 430000, China.
Weijian Hang,
Division of Cardiology, Department of Internal Medicine, Tongji
Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430000, China and Hubei Key Laboratory of Genetics and
Molecular Mechanism of Cardiologic Disorders, Huazhong University of Science
and Technology, Wuhan 430000, China.
Na Li,
Division of Cardiology, Department of Internal Medicine, Tongji
Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan 430000, China and Hubei Key Laboratory of Genetics and
Molecular Mechanism of Cardiologic Disorders, Huazhong University of Science
and Technology, Wuhan 430000, China.
Ning Zhou,
Division
of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan 430000, China and
Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic
Disorders, Huazhong University of Science and Technology, Wuhan 430000, China.
Dao
Wen Wang,
Division
of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan 430000, China and
Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic
Disorders, Huazhong University of Science and Technology, Wuhan 430000, China.
Please see the link here: https://stm.bookpi.org/ANUMS-V7/article/view/13421
No comments:
Post a Comment